195 related articles for article (PubMed ID: 16813651)
21. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
22. Tubulin inhibitors: Discovery of a new scaffold targeting extra-binding residues within the colchicine site through anchoring substituents properly adapted to their pocket by a semi-flexible linker.
Maklad RM; AbdelHafez EMN; Abdelhamid D; Aly OM
Bioorg Chem; 2020 Jun; 99():103767. PubMed ID: 32325332
[TBL] [Abstract][Full Text] [Related]
23. A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.
Ning N; Yu Y; Wu M; Zhang R; Zhang T; Zhu C; Huang L; Yun CH; Benes CH; Zhang J; Deng X; Chen Q; Ren R
Cancer Res; 2018 Oct; 78(20):5949-5957. PubMed ID: 30135190
[TBL] [Abstract][Full Text] [Related]
24. A steroid derivative with paclitaxel-like effects on tubulin polymerization.
Verdier-Pinard P; Wang Z; Mohanakrishnan AK; Cushman M; Hamel E
Mol Pharmacol; 2000 Mar; 57(3):568-75. PubMed ID: 10692498
[TBL] [Abstract][Full Text] [Related]
25. Reversible inhibition of microtubules and cell growth by the bicyclic colchicine analogue MTC.
Díez JC; Avila J; Nieto JM; Andreu JM
Cell Motil Cytoskeleton; 1987; 7(2):178-86. PubMed ID: 3581187
[TBL] [Abstract][Full Text] [Related]
26. Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring.
Álvarez R; Aramburu L; Gajate C; Vicente-Blázquez A; Mollinedo F; Medarde M; Peláez R
Bioorg Chem; 2020 May; 98():103755. PubMed ID: 32200330
[TBL] [Abstract][Full Text] [Related]
27. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.
Cheung CH; Chen HH; Kuo CC; Chang CY; Coumar MS; Hsieh HP; Chang JY
Mol Cancer; 2009 Jul; 8():43. PubMed ID: 19575780
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Novel Diarylamide
Liu X; Pang XJ; Liu Y; Liu WB; Li YR; Yu GX; Zhang YB; Song J; Zhang SY
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279387
[TBL] [Abstract][Full Text] [Related]
29. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents.
ter Haar E; Rosenkranz HS; Hamel E; Day BW
Bioorg Med Chem; 1996 Oct; 4(10):1659-71. PubMed ID: 8931935
[TBL] [Abstract][Full Text] [Related]
30. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
31. Roles of colchicine rings B and C in the binding process to tubulin.
Medrano FJ; Andreu JM; Gorbunoff MJ; Timasheff SN
Biochemistry; 1989 Jun; 28(13):5589-99. PubMed ID: 2775723
[TBL] [Abstract][Full Text] [Related]
32. Nordihydroguaiaretic acid, of a new family of microtubule-stabilizing agents, shows effects differentiated from paclitaxel.
Nakamura M; Nakazawa J; Usui T; Osada H; Kono Y; Takatsuki A
Biosci Biotechnol Biochem; 2003 Jan; 67(1):151-7. PubMed ID: 12619686
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic microtubules in human neutrophil degranulation: reversible inhibition by the colchicine analogue 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1- one.
Mollinedo F; Nieto JM; Andreu JM
Mol Pharmacol; 1989 Oct; 36(4):547-55. PubMed ID: 2682203
[TBL] [Abstract][Full Text] [Related]
34. Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells.
Rai A; Kapoor S; Naaz A; Kumar Santra M; Panda D
Biochem Pharmacol; 2017 May; 132():38-47. PubMed ID: 28242250
[TBL] [Abstract][Full Text] [Related]
35. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
36. Macrophage migration inhibitory factor induces contractile and mitochondria dysfunction by altering cytoskeleton network in the human heart.
Preau S; Montaigne D; Modine T; Fayad G; Koussa M; Tardivel M; Durocher A; Saulnier F; Marechal X; Neviere R
Crit Care Med; 2013 Jul; 41(7):e125-33. PubMed ID: 23478658
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
[TBL] [Abstract][Full Text] [Related]
38. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
39. -NH-dansyl isocolchicine exhibits a significantly improved tubulin-binding affinity and microtubule inhibition in comparison to isocolchicine by binding tubulin through its A and B rings.
Das L; Datta AB; Gupta S; Poddar A; Sengupta S; Janik ME; Bhattacharyya B
Biochemistry; 2005 Mar; 44(9):3249-58. PubMed ID: 15736935
[TBL] [Abstract][Full Text] [Related]
40. Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.
Hartley RM; Peng J; Fest GA; Dakshanamurthy S; Frantz DE; Brown ML; Mooberry SL
Mol Pharmacol; 2012 Mar; 81(3):431-9. PubMed ID: 22169850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
